| Literature DB >> 30463015 |
Barbara L Wehde1, Patrick D Rädler2, Hridaya Shrestha3, Stevi J Johnson3, Aleata A Triplett1, Kay-Uwe Wagner4.
Abstract
Janus kinases (JAKs) and their downstream STAT proteins play key roles in cytokine signaling, tissue homeostasis, and cancer development. Using a breast cancer model that conditionally lacks Janus kinase 1, we show here that JAK1 is essential for IL-6-class inflammatory cytokine signaling and plays a critical role in metastatic cancer progression. JAK1 is indispensable for the oncogenic activation of STAT1, STAT3, and STAT6 in ERBB2-expressing cancer cells, suggesting that ERBB2 receptor tyrosine kinase complexes do not directly activate these STAT proteins in vivo. A genome-wide gene expression analysis revealed that JAK1 signaling has pleiotropic effects on several pathways associated with cancer progression. We established that FOS and MAP3K8 are targets of JAK1/STAT3 signaling, which promotes tumorsphere formation and cell migration. The results highlight the significance of JAK1 as a rational therapeutic target to block IL-6-class cytokines, which are master regulators of cancer-associated inflammation.Entities:
Keywords: Cre recombinase; Janus kinase 1; MAP3K8; RNA sequencing; Stat transcription factor; breast cancer; c-Fos; gene targeting; mammary neoplasms; signal transduction
Mesh:
Substances:
Year: 2018 PMID: 30463015 PMCID: PMC6431084 DOI: 10.1016/j.celrep.2018.10.063
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423